Peginterferon Alfa

BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients
Yahoo/BusinessWire
Sun, 09/18/11 - 12:14 pm
Bristol-Myers Squibb
BMS-790052
Peginterferon Alfa
Ribavirin
hepatitis C